John Renger Cerevel Therapeutics Holdings, Inc. (CERE) insider trading activity

John Renger is Chief Scientific Officer of Cerevel Therapeutics Holdings, Inc.. Currently has a direct ownership of 0 shares of CERE, which is worth approximately $0. The most recent transaction as insider was on Aug 01, 2024, when has been sold 6,370 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

John Renger Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 01 2024	SELL Sale (or disposition) back to the issuer	-	6,370 Reduced 100.0%	0 Common Stock
Feb 07 2024	SELL Open market or private sale	$89,767 $41.54 p/Share	2,161 Reduced 25.33%	6,370 Common Stock
Feb 06 2024	BUY Exercise of conversion of derivative security	-	5,020 Added 37.05%	8,531 Common Stock
Nov 01 2022	SELL Open market or private sale	$750,000 $30.0 p/Share	25,000 Reduced 90.24%	2,704 Common Stock
Nov 01 2022	BUY Exercise of conversion of derivative security	$172,250 $6.89 p/Share	25,000 Added 47.43%	27,704 Common Stock
Oct 04 2022	SELL Open market or private sale	$750,000 $30.0 p/Share	25,000 Reduced 90.24%	2,704 Common Stock
Oct 04 2022	BUY Exercise of conversion of derivative security	$172,250 $6.89 p/Share	25,000 Added 47.43%	27,704 Common Stock
Aug 10 2022	SELL Open market or private sale	$2,235,200 $40.64 p/Share	55,000 Reduced 95.31%	2,704 Common Stock
Aug 10 2022	BUY Exercise of conversion of derivative security	$378,950 $6.89 p/Share	55,000 Added 48.8%	57,704 Common Stock
Aug 08 2022	SELL Open market or private sale	$377,500 $37.75 p/Share	10,000 Reduced 78.72%	2,704 Common Stock
Aug 08 2022	BUY Exercise of conversion of derivative security	$35,000 $3.5 p/Share	10,000 Added 44.05%	12,704 Common Stock
Aug 05 2022	SELL Open market or private sale	$650,000 $32.5 p/Share	20,000 Reduced 88.09%	2,704 Common Stock
Aug 05 2022	BUY Exercise of conversion of derivative security	$70,000 $3.5 p/Share	20,000 Added 46.83%	22,704 Common Stock
Jul 20 2022	SELL Open market or private sale	$750,000 $30.0 p/Share	25,000 Reduced 90.24%	2,704 Common Stock
Jul 20 2022	BUY Exercise of conversion of derivative security	$87,500 $3.5 p/Share	25,000 Added 47.43%	27,704 Common Stock
Jul 06 2022	SELL Open market or private sale	$35,912 $32.5 p/Share	1,105 Reduced 29.01%	2,704 Common Stock
Jul 06 2022	BUY Exercise of conversion of derivative security	$3,868 $3.5 p/Share	1,105 Added 22.49%	3,809 Common Stock
Jul 05 2022	SELL Open market or private sale	$750,000 $30.0 p/Share	25,000 Reduced 90.24%	2,704 Common Stock
Jul 05 2022	BUY Exercise of conversion of derivative security	$87,500 $3.5 p/Share	25,000 Added 47.43%	27,704 Common Stock
Apr 13 2022	SELL Open market or private sale	$1,559,250 $34.65 p/Share	45,000 Reduced 95.79%	1,980 Common Stock
Apr 13 2022	BUY Exercise of conversion of derivative security	$157,500 $3.5 p/Share	45,000 Added 48.92%	46,980 Common Stock
Mar 29 2022	SELL Open market or private sale	$350,000 $35.0 p/Share	10,000 Reduced 83.47%	1,980 Common Stock
Mar 29 2022	BUY Exercise of conversion of derivative security	$35,000 $3.5 p/Share	10,000 Added 45.5%	11,980 Common Stock
Mar 18 2022	SELL Open market or private sale	$650,000 $32.5 p/Share	20,000 Reduced 90.99%	1,980 Common Stock
Mar 18 2022	BUY Exercise of conversion of derivative security	$70,000 $3.5 p/Share	20,000 Added 47.64%	21,980 Common Stock

John Renger

Chief Scientific Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CERE shares.

Notify only if

Value

Insider Trading

Get notified when an Cerevel Therapeutics Holdings, Inc. insider buys or sells CERE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Cerevel Therapeutics Holdings, Inc.

Track Activities on CERE

Account